Navigation Links
Filter Fails to Improve PCI Outcomes in Acute Coronary Syndromes
Date:3/30/2008

Windsock-like device catches debris but doesn't avoid damage to heart

muscle

CHICAGO, March 30 /PRNewswire/ -- A device that catches bits of plaque and blood clot that break loose during percutaneous coronary intervention (PCI) has failed to show that it can reduce rates of major cardiovascular complications in patients with acute coronary syndromes, a condition that encompasses unstable angina and a type of heart attack known as non-ST-elevation myocardial infarction (NSTEMI). Although the EZ FilterWire captured debris in the bloodstream in nearly half of patients, it did not reduce damage to the heart muscle.

Investigators for the Angioplasty Balloon-Associated Coronary Debris and the EZ FilterWire (A-F) study had expected the results to be more encouraging. First, the study focused on patients with arterial blockages that appeared particularly likely to be a source of downstream debris during PCI. In addition, myonecrosis, or debris-caused damage to the heart muscle resulting from blockage of tiny blood vessels, is fairly common.

"PCI is associated with myonecrosis in about 25 percent of patients with non-STEMI acute coronary syndromes," said Mark W.I. Webster, MD, director of the cardiac catheterization laboratory at Auckland City Hospital, Auckland, New Zealand. "Although there are other mechanisms, distal embolism of atherosclerotic plaque and/or thrombus is recognized to be a frequent cause."

The A-F study is being presented today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

The EZ FilterWire is a coronary guidewire with a plastic sack shaped like a windsock attache
'/>"/>

SOURCE SCAI-ACCi2
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease
2. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
3. Tailored Clopidogrel Dosing Improves PCI Outcomes
4. Molecular Science Could Further Improve Leukemia Survival, Say St. Jude Researchers
5. Family of Three Americans Become Pain Free and Improve Their Quality of Life With Stem Cell Treatment in Mexico
6. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
7. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
8. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
9. REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
11. Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email: